CiRA and DSP aim to utilize induced pluripotent stem cells (iPS cells) for idenfying the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various pathological changes of signal transduction, and screen specific inhibitors against the signal pathway.
Under the agreement, DSP will synthesize, investigate and optimize candidate compounds, and develop the treatment for the disease found through the joint research.